IN8bio Inc (INAB)

Q: What's priced into IN8bio Inc (INAB) stock?

The snapshot provides no valuation multiple or direct measure of market expectations, so whether INAB is cheap or expensive versus peers cannot be assessed. Recent performance is below its industry cohort, and the stock has reacted down, but the evidence does not show exactly what expectations are already reflected.

Q: What does the IN8bio Inc (INAB) outlook hinge on?

The multi-year thesis hinges on clinical progress, especially whether the glioblastoma program's results support further development and whether management secures useful FDA guidance. Near term, a guidance cut or weaker jobs data could weigh on the business backdrop, while continued strength from healthcare bellwethers could support sector sentiment.

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$1.05+6.50%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge IN8bio Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.35
Annual ending 2026-12-31
Revenue	—	47.67M
EPS	—	-1.113
Annual ending 2027-12-31
Revenue	—	1.66M
EPS	—	-0.95

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Reduce net operating losses toward -$5.1 million by 2026-Q1	A primary condition in IN8bio Inc's published investment case. The stated target is net income losses <= -$5.1 million.	Improving	net income losses exceed -$5.1 million beyond 2026-Q1	Net income: $-4.781M FY2026-Q2; GAAP. Published target: net income losses <= -$5.1 million. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source published Aug 6, 2026-4,781,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 1003a786-dff7-4177-aa70-baf49487a657. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 8 of last 8 quarters. The company reported net losses ranging from $3.9 million to $7.1 million over this period, with $4.8 million loss in 2026-Q2. Cash decreased from $21.9 million in 2026-Q1 to $18.0 million in 2026-Q2. Management continues to manage operating losses and cash flow, but the trajectory shows ongoing losses and cash burn consistent with clinical-stage biopharma operations. Delivery assessment Oct 24, 2026
Advance clinical trials of gamma-delta T cell therapies	The company is focused on cancer therapies with new cell treatments.	Intact	clinical trial progress stalls or fails	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Lower negative cash from operations to <= -$4.9 million by 2026-Q1	Cash burn also improved from $6.1M to $4.9M.	Broken	cash burn exceeds -$4.9 million beyond 2026-Q1	Cash from operations: $-3.745M FY2026-Q2; GAAP. Published target: cash from operations <= -$4.9 million. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source published Aug 6, 2026-3,745,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 8 of last 8 quarters. The company reported net losses ranging from $3.9 million to $7.1 million over this period, with $4.8 million loss in 2026-Q2. Cash decreased from $21.9 million in 2026-Q1 to $18.0 million in 2026-Q2. Management continues to manage operating losses and cash flow, but the trajectory shows ongoing losses and cash burn consistent with clinical-stage biopharma operations. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	3 / 3
2026-07-25	Unavailable	Unavailable	4 / 4
2026-07-26	Unavailable	Unavailable	4 / 4
2026-07-27	Unavailable	Unavailable	4 / 4
2026-07-28	Unavailable	Unavailable	4 / 4
2026-07-29	Unavailable	Unavailable	4 / 4
2026-07-30	Unavailable	Unavailable	4 / 4
2026-07-31	Unavailable	Unavailable	4 / 4
2026-08-01	Unavailable	Unavailable	3 / 3
2026-08-02	Unavailable	Unavailable	4 / 4
2026-08-03	Unavailable	Unavailable	4 / 4
2026-08-04	Unavailable	Unavailable	4 / 4
2026-08-05	Unavailable	Unavailable	4 / 4
2026-08-06	Unavailable	Unavailable	4 / 4
2026-08-07	Unavailable	Unavailable	3 / 3
2026-08-08	Unavailable	Unavailable	3 / 3
2026-08-09	Unavailable	Unavailable	4 / 4
2026-08-10	Unavailable	Unavailable	3 / 3
2026-08-12	Unavailable	Unavailable	3 / 3
2026-08-13	Unavailable	Unavailable	3 / 3
2026-08-14	Unavailable	Unavailable	3 / 3
2026-08-15	Unavailable	Unavailable	3 / 2
2026-08-16	Unavailable	Unavailable	3 / 2
2026-08-17	Unavailable	Unavailable	3 / 2
2026-08-18	Unavailable	Unavailable	3 / 3
2026-08-19	Unavailable	Unavailable	3 / 3
2026-08-20	Unavailable	Unavailable	3 / 3
2026-08-21	Unavailable	Unavailable	3 / 3
2026-08-22	Unavailable	Unavailable	3 / 3
2026-08-23	Unavailable	Unavailable	3 / 3
2026-08-24	Unavailable	Unavailable	3 / 3
2026-08-25	Unavailable	Unavailable	3 / 3
2026-08-26	Unavailable	Unavailable	3 / 3
2026-08-27	Unavailable	Unavailable	3 / 3
2026-08-28	Unavailable	Unavailable	3 / 3
2026-08-29	Unavailable	Unavailable	3 / 3
2026-08-30	Unavailable	Unavailable	3 / 3
2026-08-31	Unavailable	Unavailable	3 / 3
2026-09-01	Unavailable	Unavailable	3 / 3
2026-09-02	Unavailable	Unavailable	3 / 3
2026-09-03	Unavailable	Unavailable	3 / 3
2026-09-04	Unavailable	Unavailable	3 / 3
2026-09-05	Unavailable	Unavailable	3 / 3
2026-09-06	Unavailable	Unavailable	3 / 3
2026-09-07	Unavailable	Unavailable	3 / 3
2026-09-08	Unavailable	Unavailable	3 / 3
2026-09-09	Unavailable	Unavailable	3 / 3
2026-09-10	Unavailable	Unavailable	3 / 3
2026-09-11	Unavailable	Unavailable	3 / 3
2026-09-12	Unavailable	Unavailable	3 / 3
2026-09-13	Unavailable	Unavailable	3 / 3
2026-09-14	Unavailable	Unavailable	3 / 3
2026-09-15	Unavailable	Unavailable	3 / 3
2026-09-16	Unavailable	Unavailable	3 / 3
2026-09-17	Unavailable	Unavailable	3 / 3
2026-09-18	Unavailable	Unavailable	3 / 3
2026-09-19	Unavailable	Unavailable	2 / 2
2026-09-20	Unavailable	Unavailable	2 / 2
2026-09-21	Unavailable	Unavailable	2 / 2
2026-09-22	Unavailable	Unavailable	2 / 2
2026-09-23	Unavailable	Unavailable	2 / 2
2026-09-24	Unavailable	Unavailable	2 / 2
2026-09-25	Unavailable	Unavailable	2 / 2
2026-09-26	Unavailable	Unavailable	2 / 2
2026-09-27	Unavailable	Unavailable	2 / 2
2026-09-28	Unavailable	Unavailable	2 / 2
2026-09-29	Unavailable	Unavailable	2 / 2
2026-09-30	Unavailable	Unavailable	2 / 2
2026-10-01	Unavailable	Unavailable	2 / 2
2026-10-02	Unavailable	Unavailable	2 / 2
2026-10-03	Unavailable	Unavailable	2 / 2
2026-10-04	Unavailable	Unavailable	2 / 2
2026-10-05	Unavailable	Unavailable	2 / 2
2026-10-06	Unavailable	Unavailable	2 / 2
2026-10-07	Unavailable	Unavailable	2 / 2
2026-10-08	Unavailable	Unavailable	2 / 2
2026-10-09	Unavailable	Unavailable	2 / 2
2026-10-10	Unavailable	Unavailable	2 / 2
2026-10-11	Unavailable	Unavailable	2 / 2
2026-10-12	Unavailable	Unavailable	2 / 2
2026-10-13	Unavailable	Unavailable	2 / 2
2026-10-14	Unavailable	Unavailable	2 / 2
2026-10-15	Unavailable	Unavailable	2 / 2
2026-10-16	Unavailable	Unavailable	2 / 2
2026-10-17	Unavailable	Unavailable	2 / 2
2026-10-18	Unavailable	Unavailable	2 / 2
2026-10-19	Unavailable	Unavailable	2 / 2
2026-10-20	Unavailable	Unavailable	2 / 2
2026-10-21	Unavailable	Unavailable	2 / 2
2026-10-22	Unavailable	Unavailable	2 / 2
2026-10-23	Unavailable	Unavailable	2 / 2
2026-10-24	Unavailable	Unavailable	2 / 2

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	4	0	0
2026-06-01	4	0	0
2026-07-01	4	0	0
2026-08-01	4	0	0
2026-09-01	4	0	0
2026-10-01	3	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 3 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Reduce net operating losses toward -$5.1 million by 2026-Q1Net income: $-4.781M
Advance clinical trials of gamma-delta T cell therapiesQualitative condition
Lower negative cash from operations to <= -$4.9 million by 2026-Q1Published status: Broken

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.9%Typical daily move · historical

Downside history

-62.9%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

IN8bio Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative growth story, not a proven compounder, with high risk and weak recent financial performance. The long-term thesis is on watch: some programs are progressing, but the evidence snapshot gives low confidence.

What's priced into IN8bio Inc

The snapshot provides no valuation multiple or direct measure of market expectations, so whether INAB is cheap or expensive versus peers cannot be assessed. Recent performance is below its industry cohort, and the stock has reacted down, but the evidence does not show exactly what expectations are already reflected.

What the fundamentals likely do

Near term, the company remains loss-making, and the next financial update carries elevated miss risk. The INB-600 and INB-619 platform is on track for preclinical animal data in the second half of 2026; glioblastoma data show progress, though the program and regulatory work remain under watch.

What IN8bio Inc hinges on